In the early stages of chronic progressive diseases like IPD, identification of sarcopenia and dynapenia is important considering the limitations of disease-preventive effects in treatments applied after diagnosis.

No abstract

No abstract

No abstract

No abstract

No abstract

No abstract

Objective: Identification of serum C-reactive protein (CRP)/albumin ratio according to disease stage in idiopathic Parkinson's disease (IPD) with the aim of collecting data about the role of inflammation and oxidative stress in etiopathogenesis and about CRP/albumin ratio's possible effects on disease progression. Materials and Methods: The study was completed with 151 patients being staged according to the Modified Hoehn and Yahr (H&Y) criteria and 150 healthy volunteers in the same age interval with patients. In our retrospective study, the Unified Parkinson disease rating scale (UPDRS) and H&Y scales were applied to the patients with IPD diagnosed according to the diagnostic criteria of the "United Kingdom Parkinson Disease Society Brain Bank". Patient and control groups had venous blood samples taken for biochemical study after 12-14 hours of fasting. Results: The serum albumin levels were lower, while serum CRP levels and CRP/albumin ratios were higher in the IPD group (p<0.05) than in the control group. Serum levels of CRP/albumin ratio significantly increased in parallel with the progression of disease stage (p<0.05). Conclusion: Our study supports the hypothesis that serum CRP/albumin ratio may be associated with the etiopathogenetic process of IPD as a biomarker of inflammation and oxidative stress. In order to detect chronic and progressive diseases such as IPD in the initial stages and to take precautions, it is important to evaluate the changes in easily accessible, cost-effective parameters such as serum CRP/albumin ratio.